DK2684888T3 - New crosslinked peptides containing non-peptide crosslinked structure, process for synthesizing crosslinked peptides and new organic compound used in the process - Google Patents

New crosslinked peptides containing non-peptide crosslinked structure, process for synthesizing crosslinked peptides and new organic compound used in the process Download PDF

Info

Publication number
DK2684888T3
DK2684888T3 DK12755137.2T DK12755137T DK2684888T3 DK 2684888 T3 DK2684888 T3 DK 2684888T3 DK 12755137 T DK12755137 T DK 12755137T DK 2684888 T3 DK2684888 T3 DK 2684888T3
Authority
DK
Denmark
Prior art keywords
crosslinked
new
organic compound
synthesizing
compound used
Prior art date
Application number
DK12755137.2T
Other languages
Danish (da)
Inventor
Mari Okumoto
Takashi Nakae
Kazuhiro Chiba
Yusuke Kono
Shuji Fujita
Hideaki Suzuki
Original Assignee
Jitsubo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jitsubo Co Ltd filed Critical Jitsubo Co Ltd
Application granted granted Critical
Publication of DK2684888T3 publication Critical patent/DK2684888T3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/006—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length of peptides containing derivatised side chain amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/06—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents
    • C07K1/061—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using protecting groups or activating agents using protecting groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK12755137.2T 2011-03-09 2012-02-28 New crosslinked peptides containing non-peptide crosslinked structure, process for synthesizing crosslinked peptides and new organic compound used in the process DK2684888T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2011052107 2011-03-09
PCT/JP2012/054895 WO2012121057A1 (en) 2011-03-09 2012-02-28 Novel cross-linked peptides containing non-peptide cross-linked structure, method for synthesizing cross-linked peptides, and novel organic compound used in method

Publications (1)

Publication Number Publication Date
DK2684888T3 true DK2684888T3 (en) 2019-08-19

Family

ID=46798025

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12755137.2T DK2684888T3 (en) 2011-03-09 2012-02-28 New crosslinked peptides containing non-peptide crosslinked structure, process for synthesizing crosslinked peptides and new organic compound used in the process

Country Status (7)

Country Link
US (2) US9376467B2 (en)
EP (1) EP2684888B1 (en)
JP (1) JP6150726B2 (en)
CN (1) CN103415530A (en)
DK (1) DK2684888T3 (en)
ES (1) ES2742299T3 (en)
WO (1) WO2012121057A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5649825B2 (en) 2007-01-31 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Stabilized p53 peptides and methods of use thereof
ES2430067T3 (en) 2007-03-28 2013-11-18 President And Fellows Of Harvard College Sewn polypeptides
KR20170058446A (en) 2010-08-13 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 Peptidomimetic macrocycles
RU2639523C2 (en) 2011-10-18 2017-12-21 Эйлерон Терапьютикс, Инк. Peptidomimetic macrocycles and their application
CA2864120A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CA2862038C (en) 2012-02-15 2021-05-25 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
JP6526563B2 (en) 2012-11-01 2019-06-05 エイルロン セラピューティクス，インコーポレイテッド Disubstituted amino acids and methods for their preparation and use
CN107072946B (en) * 2014-09-05 2022-01-11 诺华股份有限公司 Lipids and lipid compositions for delivery of active agents
CA2961029A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
MX2017003797A (en) 2014-09-24 2017-06-15 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof.
CN107614003A (en) 2015-03-20 2018-01-19 艾瑞朗医疗公司 Peptidomimetic macrocyclic compound and application thereof
US10023613B2 (en) 2015-09-10 2018-07-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles as modulators of MCL-1
WO2017131138A1 (en) * 2016-01-29 2017-08-03 シチズン時計株式会社 Inspection liquid for inspecting whether leather has been treated using hexavalent chromium reducing compound

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0673388B1 (en) 1992-06-02 1998-10-14 Nycomed Imaging As Double chain peptide compounds having hemoregulatory activity
SE9302247L (en) 1993-06-30 1994-12-31 Cultor Oy New crosslinker and its use
IL109943A (en) * 1994-06-08 2006-08-01 Develogen Israel Ltd Conformationally constrained backbone cyclized peptide analogs
SE9604341D0 (en) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
US6265535B1 (en) * 1997-05-30 2001-07-24 The Trustees Of The University Of Pennsylvania Peptides and peptide analogues designed from binding sites of tumor necrosis factor receptor superfamily and their uses
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
AU777634B2 (en) * 1999-07-28 2004-10-28 Kazuhiro Aoki Methods of inhibiting osteoclastogenesis
US6682739B1 (en) 1999-07-28 2004-01-27 The Trustees Of The University Of Pennsylvania Methods of inhibiting osteoclastogenesis
JP4680362B2 (en) 2000-09-22 2011-05-11 株式会社石井工作研究所 Electronic component manufacturing method and manufacturing apparatus
JP2004059509A (en) 2002-07-30 2004-02-26 Nokodai Tlo Kk Amino acid reagent for liquid phase peptide synthesis
JP4525982B2 (en) 2003-09-26 2010-08-18 シェーリング コーポレイション Macrocyclic inhibitor of NS3 serine protease of hepatitis C virus
US20110150835A1 (en) 2003-09-26 2011-06-23 Schering Corporation Macrocyclic Inhibitors of Hepatitis C Virus NS3 Serine Protease
EP1680443B9 (en) 2003-11-05 2014-09-03 Dana-Farber Cancer Institute, Inc. Stabilized alpha helical peptides and uses thereof
DE102004032608A1 (en) * 2004-07-05 2006-02-16 United Mobile Holding Ltd. Callback procedure in a communication system
EP1927584B1 (en) 2005-09-20 2016-11-30 Jitsubo Co., Ltd. Carrier for separation, method for separation of compound, and method for synthesis of peptide using the carrier
ES2546808T3 (en) 2006-03-24 2015-09-28 Jitsubo Co., Ltd. Reagent for organic synthesis and reaction method of organic synthesis with said reagent
WO2008033505A1 (en) 2006-09-13 2008-03-20 University Of South Florida Biocomposite for artificial tissue design
JP2010119382A (en) * 2008-10-23 2010-06-03 Osaka Univ Method for fluorescently labeling protein
US8569453B2 (en) 2009-03-12 2013-10-29 Ajinomoto Co., Inc. Fluorene compound
EP2415745A4 (en) 2009-03-30 2014-06-11 Ajinomoto Kk Diphenylmethane compound
WO2010147666A1 (en) * 2009-06-19 2010-12-23 Memorial Sloan-Kettering Cancer Center Compounds useful as carbonic anhydrase modulators and uses thereof
WO2011008260A2 (en) * 2009-07-13 2011-01-20 President And Fellows Of Harvard College Bifunctional stapled polypeptides and uses thereof
JP2014101274A (en) * 2011-03-09 2014-06-05 Jitsubo Co Ltd Pharmaceutical composition using mimic peptide of tnf receptor loop peptide comprising new crosslinked structure

Also Published As

Publication number Publication date
CN103415530A (en) 2013-11-27
EP2684888A1 (en) 2014-01-15
WO2012121057A1 (en) 2012-09-13
EP2684888A4 (en) 2015-01-21
US10633418B2 (en) 2020-04-28
US20160333052A1 (en) 2016-11-17
JPWO2012121057A1 (en) 2014-07-17
JP6150726B2 (en) 2017-06-21
EP2684888B1 (en) 2019-05-15
ES2742299T3 (en) 2020-02-13
US20130345393A1 (en) 2013-12-26
US9376467B2 (en) 2016-06-28

Similar Documents

Publication Publication Date Title
DK2684888T3 (en) New crosslinked peptides containing non-peptide crosslinked structure, process for synthesizing crosslinked peptides and new organic compound used in the process
DK3425805T3 (en) Sample array encoding for low latency
DK2925782T3 (en) ANTI-CD47 ANTIBODIES AND PROCEDURES FOR USE THEREOF
DK3494997T3 (en) INducible DNA-Binding Proteins and Tools for Genome Reperturation and Their Uses
BR112012018101A2 (en) apparatus, and method.
DK2859017T3 (en) ANTIBODIES INCLUDING PLACE-SPECIFIC NON-NATURAL AMINO ACID, PROCEDURE FOR MANUFACTURING ITS AND METHODS OF USE THEREOF
DK2591006T3 (en) PROCESSABLE SINGLE CHAIN MOLECULES AND POLYPEPTIDES MADE BY USING THEREOF
DK3223284T3 (en) PROCESS FOR CREATING AND MAINTAINING THE HIGHLIGHTS FRC
DK3661204T3 (en) PICTURE PREDICTION-DECODING DEVICE, PICTURE PREDICTION-DECODING PROCEDURE
IT1403054B1 (en) BOTTLE.
DK2794907T3 (en) METHODS AND MATERIALS FOR ASSESSING HETEROZYGOSITY LOSS
BR112014015994A2 (en) process.
DK3421597T3 (en) CHRYSOSPORIUM LUCKNOWENSE PROTEIN PRODUCTION SYSTEM
DK2677029T3 (en) Methods for producing proteolytically processed polypeptides
BR112012016424A2 (en) apparatus, and method.
DK2310501T3 (en) New regulatory elements
DK3388687T3 (en) VOLTAGE APPLICATION DEVICE, ROTATING DEVICE AND VOLTAGE APPLICATION PROCEDURE
DK3435087T3 (en) UNKNOWN PROCESSES FOR PROTEIN EVOLUTION
DK3001686T3 (en) DEVICE, PROCEDURE AND PROGRAM FOR BIPREPREDIC IMAGE DECODING
DK2618842T3 (en) HOWEVER, UNKNOWN IMMUNICATIVE PROCEDURE
IT1398984B1 (en) PERFECT LOCK-DOOR DEVICE.
DK2650049T3 (en) Hydrogen treatment catalyst and process for its preparation
CO6980642A2 (en) Transportable Reformer
BR112012024474A2 (en) process
DK2683371T3 (en) COMPOUNDS AND METHODS FOR IMPROVING THE DETERIORED ENDOGEN FIBRINOLYSE USING HISTONDEACETYLASE INHIBITORS